Chronic Myeloid Leukemia Committee (CML)

Committee Chairman:

Meinolf Suttorp

Committee Members:



Clinical Trials:


1) International Registry for Chronic Myeloid Leukemia in children and adolescents (I‐CML‐Ped study)

2) Kinetic of molecular responses in children and adolescents with de novo Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) treated with Imatinib



Recent Publications:

Chaudhury S, Sparapani R, Hu ZH, Nishihori T, Abdel-Azim H, Malone A, Olsson R, Hamadani M, Daly A, Bacher U, Wirk BM, Kamble RT, Gale RP, Wood WA, Hale G, Wiernik PH, Hashmi SK, Marks D, Ustun C, Munker R, Savani BN, Alyea E, Popat U, Sobecks R, Kalaycio M, Maziarz R, Hijiya N, Saber W. Outcomes of Allogeneic Hematopoietic Cell Transplantation in Children and Young Adults with Chronic Myeloid Leukemia: A CIBMTR Cohort Analysis. Biol Blood Marrow Transplant. 22(6):1056-1064 (2016).

Faraci M, Matthes-Martin S, Lanino E, Morreale G, Ferretti M, Giardino S, Micalizzi C, Balduzzi A. Two pregnancies shortly after transplantation with reduced intensity conditioning in chronic myeloid leukemia. Pediatr Transplant  20(1):158-161 (2016)

Freedman JL, Desai AV, Bailey LC, Aplenc R, Burnworth B, Zehentner BK, Teachey DT, Wertheim G. Atypical Chronic Myeloid Leukemia in Two Pediatric Patients. Pediatr Blood Cancer. 63(1):156-159 (2016).

Giona F, Moleti ML, De Benedittis D, Santopietro M, Nanni M, Testi AM, Orlando S, Iori AP, Piciocchi A, Gottardi E, Barberi W, Diverio D, Saglio G, Foà R. Can chronic myeloid leukaemia in children and adolescents be successfully treated without haematopoietic stem cell transplant? A single centre experience. Br J Haematol. 173(5):749-753 (2016).

Hijiya N, Schultz KR, Metzler M, Millot F, Suttorp M: Pediatric chronic myeloid leukemia is a unique disease that requires a different approach. (Review). Blood 127(4):392-399 (2016).

Kurosawa H, Tanizawa A, Tono C, Watanabe A, Shima H, Ito M, Yuza Y, Hotta N, Muramatsu H, Okada M, Kajiwara R, Moriya Saito A, Mizutani S, Adachi S, Horibe K, Ishii E, Shimada H. Leukostasis in Children and Adolescents with Chronic Myeloid Leukemia: Japanese Pediatric Leukemia/Lymphoma Study Group. Pediatr Blood Cancer 63(3):406-411 (2016)

Proschmann R, Baldow C, Rothe T, Suttorp M, Thiede C, Tauer JT, Müller CM, Hochhaus A, Roeder I, Glauche I.Response dynamics of pediatric patients with chronic myeloid leukemiaon imatinib therapy: statistical analysis and model-based predictions. (Letter to the editor).  Haematologica, 2016 Nov 17. haematol.2016.154138. [Epub ahead of print]

Samis J, Lee P, Arceci RJ, Suttorp M, Hijiya N. Recognizing endocrinopathies associated with tyrosine kinase inhibitor therapy in children with chronic myelogenous leukemia. (Review) Pediatr Blood Cancer 63(8):1332-1338 (2016).



Besides the gathering together at the annual I-BFM meeting, members of the I-BFM-CML committee regularly convene at the Annual Meeting of the American Society of Hematology (ASH) in December every year. Also, the John Goldman Conferences on CML (taking place in varying towns in the USA in Sept./Oct. in even years and at Estoril/Portugal in Sept. in uneven years) is attended by some members to foster exchange of knowledge on CML with colleagues form the adult hematology.

In a national context, committee members of every participating country are highly encouraged to organize meetings on pediatric CML – ideally together with internal hematology colleagues – with the aim to distribute knowledge and management of CML among pediatricians. So far, a one-day meeting in France (Les Leucemies Myeloides Chroniques de l’enfant et de l’adolescent, Paris, Hotel Robert Debre, 15. Jan 2016), a joint adult/pediatric session at the Annual German Cancer Kongress (Berlin, 27. Feb. 2016); a joint session on CML held during the Meeting of the Hematology Society of Cordoba with GATLA in Argentina (IV Jornadas Internacionales de Hematologia, Congresso GATLA 2016, Cordoba 29. Oct 2016) supported the approach of collecting data on i) pediatric CML into the international registry at Poitiers, ii) to promote the transition of adolescent young adults (AYAs) to our internal hematology colleagues and iii) to exchange ideas on characteristics of CML which in children are either identical or differ from what is typically found in elderly patients. The past and present chairmen of the CML committee (Frederic Millot, Meinolf Suttorp) express their willingness to support national meetings with slides or talks on selected topics of CML management and/or general teaching lessons on request.




Meinolf Suttorp